Prognostic values of microRNA-130 family expression in patients with cancer: a meta-analysis and database test
Abstract Background Emerging evidence shows that microRNA-130 (miRNA-130) family may be useful as prognostic biomarkers in cancer. However, there is no confirmation in an independent validation study. The aim of this study was to summarize the prognostic value of miRNA-130 family (miRNA-130a and miR...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-10-01
|
Series: | Journal of Translational Medicine |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12967-019-2093-y |
id |
doaj-5e709f8b203247fba9a0e4de4d2916ce |
---|---|
record_format |
Article |
spelling |
doaj-5e709f8b203247fba9a0e4de4d2916ce2020-11-25T03:44:23ZengBMCJournal of Translational Medicine1479-58762019-10-0117111410.1186/s12967-019-2093-yPrognostic values of microRNA-130 family expression in patients with cancer: a meta-analysis and database testZhen Peng0Fujiao Duan1Jingjing Yin2Yajing Feng3Zhongyu Yang4Jia Shang5Department of Infectious Disease, Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou UniversityMedical Research Office, Affiliated Cancer Hospital of Zhengzhou UniversityCollege of Public Health, Zhengzhou UniversityDepartment of Nosocomial Infection Management, The First Affiliated Hospital of Zhengzhou UniversityCollege of Art and Science, The Ohio State UniversityDepartment of Infectious Disease, Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou UniversityAbstract Background Emerging evidence shows that microRNA-130 (miRNA-130) family may be useful as prognostic biomarkers in cancer. However, there is no confirmation in an independent validation study. The aim of this study was to summarize the prognostic value of miRNA-130 family (miRNA-130a and miRNA-130b) for survival in patients with cancer. Methods The pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated to estimate the association strength between miRNA-130 family expression and prognosis. Kaplan–Meier plotters were used to verify the miRNA-130b expression and overall survival (OS). Results A total of 2141 patients with OS and 1159 patients with disease-free survival (DFS)/progression-free survival (PFS) were analyzed in evidence synthesis. For the miRNA-130a, the overall pooled effect size (HR) was HR 1.58 (95% CI: 1.21–2.06, P < 0.001). Tissue and serum expression of miRNA-130a was significantly associated with the OS (HR = 1.54, 95% CI: 1.11–2.14, P = 0.009; HR = 1.65, 95% CI: 1.14–2.38, P = 0.008), and in gastric cancer (HR = 1.81, 95% CI: 1.34–2.45, P < 0.001). For the miRNA-13b, a statistical correlation was observed between high miRNA-130b expression and poor OS in patients with cancer (HR = 1.95, 95% CI: 1.47–2.59, P < 0.001), especially in tissue sample (HR = 2.01, 95% CI: 1.39–2.91, P < 0.001), Asian (HR = 2.55, 95% Cl: 1.77–3.69, P < 0.001) and hepatocellular carcinoma (HR = 1.87, 95% CI: 1.23–2.85, P = 0.004). The expression of miRNA-130b was significantly correlated with DFS/PFS (HR = 1.53, 95% CI: 1.31–1.77, P < 0.001), in tissue (HR = 1.98, 95% CI: 1.50–2.62, P < 0.001) and serum (HR = 1.37, 95% CI: 1.15–1.64, P < 0.001), especially in HCC (HR = 1.98, 95% CI: 1.50, 2.62, P < 0.001). In database test, a significant correlation between high miRNA-130b expression and poor OS for HCC patients was observed (HR = 1.55, 95% CI: 1.01, 2.35, P = 0.0045). Conclusion The high expression of miRNA-130 family might predict poor prognosis in cancer patients. Prospectively, combining miRNA-130a and miRNA-130b may be considered as powerful prognostic predictor for clinical application.http://link.springer.com/article/10.1186/s12967-019-2093-ymiRNA-130amiRNA-130bCancerPrognosisSystematic evaluation |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Zhen Peng Fujiao Duan Jingjing Yin Yajing Feng Zhongyu Yang Jia Shang |
spellingShingle |
Zhen Peng Fujiao Duan Jingjing Yin Yajing Feng Zhongyu Yang Jia Shang Prognostic values of microRNA-130 family expression in patients with cancer: a meta-analysis and database test Journal of Translational Medicine miRNA-130a miRNA-130b Cancer Prognosis Systematic evaluation |
author_facet |
Zhen Peng Fujiao Duan Jingjing Yin Yajing Feng Zhongyu Yang Jia Shang |
author_sort |
Zhen Peng |
title |
Prognostic values of microRNA-130 family expression in patients with cancer: a meta-analysis and database test |
title_short |
Prognostic values of microRNA-130 family expression in patients with cancer: a meta-analysis and database test |
title_full |
Prognostic values of microRNA-130 family expression in patients with cancer: a meta-analysis and database test |
title_fullStr |
Prognostic values of microRNA-130 family expression in patients with cancer: a meta-analysis and database test |
title_full_unstemmed |
Prognostic values of microRNA-130 family expression in patients with cancer: a meta-analysis and database test |
title_sort |
prognostic values of microrna-130 family expression in patients with cancer: a meta-analysis and database test |
publisher |
BMC |
series |
Journal of Translational Medicine |
issn |
1479-5876 |
publishDate |
2019-10-01 |
description |
Abstract Background Emerging evidence shows that microRNA-130 (miRNA-130) family may be useful as prognostic biomarkers in cancer. However, there is no confirmation in an independent validation study. The aim of this study was to summarize the prognostic value of miRNA-130 family (miRNA-130a and miRNA-130b) for survival in patients with cancer. Methods The pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated to estimate the association strength between miRNA-130 family expression and prognosis. Kaplan–Meier plotters were used to verify the miRNA-130b expression and overall survival (OS). Results A total of 2141 patients with OS and 1159 patients with disease-free survival (DFS)/progression-free survival (PFS) were analyzed in evidence synthesis. For the miRNA-130a, the overall pooled effect size (HR) was HR 1.58 (95% CI: 1.21–2.06, P < 0.001). Tissue and serum expression of miRNA-130a was significantly associated with the OS (HR = 1.54, 95% CI: 1.11–2.14, P = 0.009; HR = 1.65, 95% CI: 1.14–2.38, P = 0.008), and in gastric cancer (HR = 1.81, 95% CI: 1.34–2.45, P < 0.001). For the miRNA-13b, a statistical correlation was observed between high miRNA-130b expression and poor OS in patients with cancer (HR = 1.95, 95% CI: 1.47–2.59, P < 0.001), especially in tissue sample (HR = 2.01, 95% CI: 1.39–2.91, P < 0.001), Asian (HR = 2.55, 95% Cl: 1.77–3.69, P < 0.001) and hepatocellular carcinoma (HR = 1.87, 95% CI: 1.23–2.85, P = 0.004). The expression of miRNA-130b was significantly correlated with DFS/PFS (HR = 1.53, 95% CI: 1.31–1.77, P < 0.001), in tissue (HR = 1.98, 95% CI: 1.50–2.62, P < 0.001) and serum (HR = 1.37, 95% CI: 1.15–1.64, P < 0.001), especially in HCC (HR = 1.98, 95% CI: 1.50, 2.62, P < 0.001). In database test, a significant correlation between high miRNA-130b expression and poor OS for HCC patients was observed (HR = 1.55, 95% CI: 1.01, 2.35, P = 0.0045). Conclusion The high expression of miRNA-130 family might predict poor prognosis in cancer patients. Prospectively, combining miRNA-130a and miRNA-130b may be considered as powerful prognostic predictor for clinical application. |
topic |
miRNA-130a miRNA-130b Cancer Prognosis Systematic evaluation |
url |
http://link.springer.com/article/10.1186/s12967-019-2093-y |
work_keys_str_mv |
AT zhenpeng prognosticvaluesofmicrorna130familyexpressioninpatientswithcancerametaanalysisanddatabasetest AT fujiaoduan prognosticvaluesofmicrorna130familyexpressioninpatientswithcancerametaanalysisanddatabasetest AT jingjingyin prognosticvaluesofmicrorna130familyexpressioninpatientswithcancerametaanalysisanddatabasetest AT yajingfeng prognosticvaluesofmicrorna130familyexpressioninpatientswithcancerametaanalysisanddatabasetest AT zhongyuyang prognosticvaluesofmicrorna130familyexpressioninpatientswithcancerametaanalysisanddatabasetest AT jiashang prognosticvaluesofmicrorna130familyexpressioninpatientswithcancerametaanalysisanddatabasetest |
_version_ |
1724515380121042944 |